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Background.The objective of this study was to identify the bacteria most frequently responsible for urinary tract infection (UTI) in
the population of under-2-year-olds in our geographic area and to evaluate the activity of antibiotics widely used for UTI treatment
during a 4-year study period. Materials and Methods. A retrospective analysis was conducted of data on the identification and
susceptibility of microorganisms isolated in urine samples from children under 2 years of age. Results.A total of 1,045 uropathogens
were isolated. Escherichia coli accounted for the majority (60.3%) of these, followed by Enterococcus faecalis (22.4%) and Klebsiella
spp. (6.5%). The highest E. coli susceptibility rates (>90%) were to piperacillin-tazobactam, cefuroxime, cefotaxime, ceftazidime,
imipenem, gentamicin, nitrofurantoin, and fosfomycin, and the lowest were to amoxicillin-clavulanic acid and cotrimoxazole.
Among all bacteria isolated, we highlight the overall high activity of piperacillin-tazobactam, imipenem, nitrofurantoin, and
fosfomycin against both community and hospital isolates and the reduced activity of amoxicillin-clavulanic acid, cephalosporins,
gentamicin, and cotrimoxazole.There was no significant change in the total activity of any of the studied antibiotics over the 4-year
study period. Conclusion. Empiric treatment with amoxicillin-clavulanic acid, cotrimoxazole, cephalosporins, and gentamicin may
be inadequate due to their limited activity against uropathogens in our setting.
1. Introduction
Urinary tract infections (UTIs) are frequent during child-
hood, with a prevalence of 2–9% depending on the age and
gender. The specificity of clinical manifestations decreases
with younger age, and around 5–8% of under-2-year-olds
may present fever as sole UTI symptom [1]. Febrile UTI
in this age group can be associated with permanent renal
lesions, and bacterial infection of the kidney is detected
by cortical imaging in 50–85% of children with a first
febrile UTI, regardless of the presence of major urinary tract
abnormalities [2]. It is therefore important to obtain a precise
clinical and etiological diagnosis, start early and effective
treatment, and document the integrity of the urinary tract in
order to avoid recurrent infections, complications (e.g., renal
scarring), and sequelae (e.g., hypertension and chronic renal
disease) [3–5].
In both infants and adults, the main causative agent of
UTI is Escherichia coli, whose antibiotic susceptibility pattern
is the first to be examined in selecting empiric antibiotic
treatment. Other fecal bacteria that occasionally cause UTI
are Klebsiella spp., Proteus mirabilis, other Gram-negative
enteric bacilli, and enterococci [6].
Depending on the age of the patient and the severity of the
disease, published guidelines recommend parenteral antibi-
otics followed by oral antibiotics for the initial treatment
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of infant UTI [3, 7, 8]. Effective empiric treatment requires
knowledge of the microorganisms involved and awareness
of the antibiotic susceptibility patterns of the most frequent
uropathogens in each geographic setting and their evolution
[9–11]. Consequently, the objectives of the present study were
to identify the bacteria most frequently responsible for UTI
in the pediatric population aged under 2 years in our care
setting, to determine their susceptibility to the antibiotics
habitually used in this population, and to evaluate the activity
against all isolates of antibiotics widely used for the treatment
of community- and hospital-acquired UTIs.
2. Methods
Themethodology used in this study was previously reported
by our group [10]. A retrospective analysis was conducted
of laboratory data routinely collected by the Microbiol-
ogy Department of Granada University Hospital Complex
(southern Spain) on the identification and susceptibility of all
consecutive bacteria isolated from urine samples of children
under 2 years of age with a first-time symptomatic, culture-
verified UTI diagnosed between January 2011 and December
2014.
The study included samples obtained bymidstreamclean-
catch, bladder catheterization, or suprapubic bladder aspi-
ration. The microbiological diagnosis of UTI required ≥105
colony-forming units (CFU)/mL of a single microorganism
in midstream, or ≥104 CFU/mL of a single microorganism in
catheter samples, or any bacterial growth in urine obtained
by suprapubic bladder aspiration. Urine cultures with growth
of more than two microorganisms were considered contami-
nated.
The following samples were excluded: (i) urine samples
obtained by plastic bag applied to the perineum, only valid
when the result is negative; (ii) samples from previously
hospitalized individuals; (iii) those from individuals who had
received antibiotic therapy during the 6 months before the
UTI episode, and (iv) duplicate positive urine cultures (i.e.,
of the same genus or species obtained sequentially from the
same UTI episode). Furthermore, if a patient provided more
than one urine sample, regardless of the origin (community
or hospital), an interval of at least 6 months had to elapse
before the second sample was included in the study.
The MicroScan system (Siemens Healthcare Diagnos-
tics, Madrid, Spain) was used for identification and sus-
ceptibility profiling of all bacteria from positive urine cul-
tures. Amoxicillin-clavulanic acid, piperacillin-tazobactam,
cefuroxime, cefotaxime, ceftazidime, imipenem, gentam-
icin, cotrimoxazole, nitrofurantoin, and fosfomycin were
tested against Enterobacteriaceae. Piperacillin-tazobactam,
ceftazidime, imipenem, and gentamicin were tested against
nonfermenting Gram-negative bacilli. Ampicillin, nitrofu-
rantoin, and fosfomycin were tested against Enterococcus spp.
Isolates were categorized as susceptible, intermediate,
or resistant to each antibiotic according to Clinical and
Laboratory Standards Institute (CLSI) classifications [12].The
clinical categorization of all isolates against nitrofurantoin
followed the recommendations of the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) [13]. For
each study year and each bacterial species identified, the pro-
portion of susceptible organisms was calculated by dividing
the number of urinary isolates susceptible to each antibiotic
by the number of organisms tested against that antimicrobial
agent, grouping together intermediately resistant and resis-
tant organisms.
We evaluated the activity of each antibiotic against all
bacteria isolated during the 4-year study period, making
the following assumptions: (1) Each of the aforementioned
antibiotics is potentially active against enterobacteria; (2)
amoxicillin-clavulanic acid, cefuroxime, cefotaxime, nitro-
furantoin, and fosfomycin have no activity against nonfer-
menting Gram-negative bacilli, and Pseudomonas aeruginosa
is intrinsically resistant to cotrimoxazole; (3) among ente-
rococci, the response to ampicillin predicts the response
to amoxicillin-clavulanic acid, piperacillin-tazobactam, and
imipenem, while cefuroxime, cefotaxime, ceftazidime, gen-
tamicin, and cotrimoxazole are not clinically active against
these microorganisms [14]; (4) the activity of fosfomycin
against enterobacteria and enterococci can be assessed by
using the cutoff points recommended by the CLSI for this
antibiotic against E. coli and Enterococcus faecalis, respec-
tively [15, 16]; and (5) the activity of nitrofurantoin against
enterobacteria can be assessed by using the cutoff points
recommended by the EUCAST for this antibiotic in E. coli.
A descriptive statistical analysis was performed, and dif-
ferences in susceptibility rates were analyzed using Pearson’s
𝜒2 test and contingency tables with Fisher’s exact test. Logistic
regression was used to analyze the evolution of antibiotic
activity against isolated bacteria inUTIs over the 4-year study
period. STATA 13.1 (StataCorp, TX, USA) was used for all
analyses. 𝑃 < 0.05 was considered significant in all tests.
2.1. Ethics Statements. The study protocol was carried out
in accordance with the Declaration of Helsinki and “Com-
mission of Ethics and Health Research of the Hospital
Centres and Districts of Healthcare” (“Comisión de Ética e
Investigación Sanitaria de los Centros Hospitalarios y Distritos
de Atención Sanitaria”). This was a noninterventional study
involving only routine procedures. Biological material was
used solely for standard UTI diagnosis prescribed by physi-
cians, and there was no additional sampling or modification
of the standard laboratory protocol. Data analyses were
carried out using an anonymous database. For these reasons,
no approval was required according to national guidelines.
Permission to access and use the data was granted by the
Unit for Clinical Management of Infectious Diseases and
Clinical Microbiology of the University Hospital Complex of
Granada, Spain.
3. Results
Over the 4-year study period, the 1,045 bacteria identified
included 811 (77.6%) Gram-negative bacilli (including 790
Enterobacteriaceae and 21 P. aeruginosa) and 234 (22.4%)
Gram-positive cocci (all E. faecalis). E. coli was the most
frequently identified UTI agent in each year (60.3% of all iso-
lates; range, 58.1%–62.1%) in both community (61.1%; range,
59.7%–63.0%) and hospital (57.4%; range, 48.9%–64.7%)
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isolates, followed by E. faecalis (22.4%; range, 18.6%–27.8%)
and Klebsiella spp. (6.5%; range, 4.8%–8.0%). Other bac-
teria (Proteus spp., Enterobacter spp., Citrobacter spp., Ser-
ratia marcescens, Morganella morganii, and P. aeruginosa)
accounted for only 11.3% of community isolates and 9.0% of
hospital isolates. No staphylococci or group B streptococci
were isolated.
3.1. Antibiotic Susceptibility of the Isolated Bacteria. Table 1
exhibits the antimicrobial susceptibilities of the most fre-
quent microorganisms, E. coli and E. faecalis. E. coli showed
high susceptibility to piperacillin-tazobactam, cefuroxime,
cefotaxime, ceftazidime, imipenem, gentamicin, nitrofuran-
toin, and fosfomycin, with annual resistance rates<10%; how-
ever, resistance to amoxicillin-clavulanic acid, and cotrimox-
azole, key antibiotics in the oral treatment of community-
acquired UTIs, was recorded in at least 20–30% of E. coli
isolates inmost years.There were no significant differences in
total susceptibility between the community and hospital iso-
lates (amoxicillin-clavulanic acid [𝑝 = 0.910], piperacillin-
tazobactam [𝑝 = 0.060], cefuroxime [𝑝 = 1.000], cefotaxime
[𝑝 = 0.070], ceftazidime [𝑝 = 0.074], imipenem [𝑝 =
1.000], gentamicin [𝑝 = 1.000], cotrimoxazole [𝑝 = 0.064],
nitrofurantoin [𝑝 = 1.000], or fosfomycin [𝑝 = 0.213]).
In general, isolates ofKlebsiella pneumoniae andKlebsiella
oxytoca species were highly susceptible, although there was
wide variability in the percentages of susceptibility to differ-
ent antibiotics (range 63–100%), with no significant differ-
ences between community and hospital isolates (amoxicillin-
clavulanic acid [𝑝 = 1.000], piperacillin-tazobactam [𝑝 =
0.672], cefuroxime [𝑝 = 1.000], cefotaxime [𝑝 = 0.533],
ceftazidime [𝑝 = 0.120], imipenem [𝑝 = 1.000], gentamicin
[𝑝 = 1.000], cotrimoxazole [𝑝 = 0.579], nitrofurantoin [𝑝 =
0.334], and fosfomycin [𝑝 = 0.276]).
The incidence of ESBL-producing E. coli or Klebsiella
spp. among community and hospital isolates was very low
(5 isolates in 2012, 1 in 2013, and 6 in 2014); hence, their
influence on the activity of beta-lactam antibiotics (mainly
the cephalosporins studied) was also low.
Other Enterobacteriaceae represented 10.1% of commu-
nity isolates and 4.5% of hospital isolates. Considering all
species together, the percentages of susceptibility to the
different study antibiotics were highly variable in the dif-
ferent years, between 8% to nitrofurantoin and 100% to
some beta-lactam antibiotics (piperacillin-tazobactam and
cephalosporins). This group showed high susceptibility to
piperacillin-tazobactam, cefuroxime, cefotaxime, and cef-
tazidime, with annual resistance rates <10%, whereas resis-
tance to amoxicillin-clavulanic acid, imipenem, gentamicin,
cotrimoxazole, nitrofurantoin, and fosfomycin was recorded
in at least 20–30% of isolates in most years. The resistance
rates of these bacteria to amoxicillin-clavulanic acid were
higher in hospital isolates (𝑝 = 0.011), but there was no
difference between community and hospital isolates in resis-
tance rates to any other antibiotic.
P. aeruginosa exhibited high susceptibility to piperacillin-
tazobactam, ceftazidime, imipenem, and gentamicin, with
no significant differences between community and hospital
isolates. However, the reduced number of isolates during
the 4-year study period (21 isolates; 1.2% of community
isolates and 4.5% of hospital isolates) prevents the drawing
of meaningful comparisons.
As shown in Table 1, we highlight the elevated fre-
quency of E. faecalis and its high rates of susceptibility to
ampicillin (100%), nitrofurantoin (94–100%), and fosfomycin
(94–100%) in both community and hospital isolates, with no
significant differences between them (𝑝 = 1.000).
3.2. Evolution of Antibiotic Activity against Isolated Bacteria
in UTIs. Figure 1 depicts the activity of the tested antibiotics
against the 1,045 bacteria isolated in urine during the 4-
year study period. The activity of cefuroxime (𝑝 = 0.002),
cefotaxime (𝑝 = 0.001), ceftazidime (𝑝 = 0.009), and cotri-
moxazole (𝑝 = 0.001) was significantly higher in community-
origin than in hospital-origin isolates; however, amoxicillin-
clavulanic acid (𝑝 = 0.346), piperacillin-tazobactam (𝑝 =
0.176), imipenem (𝑝 = 0.144), gentamicin (𝑝 = 0.144), fos-
fomycin (𝑝 = 0.314), and nitrofurantoin (𝑝 = 0.164) showed
no difference in activity between community- and hospital-
origin isolates.
There was no significant change in the total activity
of any of the studied antibiotics over the 4-year study
period (amoxicillin-clavulanic acid [𝑝 = 0.624], piperacillin-
tazobactam [𝑝 = 0.945], cefuroxime [𝑝 = 0.192], cefotaxime
[𝑝 = 0.124], ceftazidime [𝑝 = 0.131], imipenem [𝑝 = 0.161],
gentamicin [𝑝 = 0.274], fosfomycin [𝑝 = 0.490], nitrofur-
antoin [𝑝 = 0.462], or cotrimoxazole [𝑝 = 0.869]). How-
ever, the activity of cefuroxime, cefotaxime, ceftazidime,
and gentamicin against hospital-origin isolates significantly
decreased (𝑝 < 0.001), as shown in Figure 1.
4. Discussion
Our research group previously published a retrospective
analysis on the identification and susceptibility pattern of all
bacteria isolated from urine samples with microbiological
confirmation of UTI in the Microbiology Department of
Granada University Hospital Complex (Granada, Spain)
between January 2006 and December 2012 [10]. This hospital
complex meets the demands of the North Hospital Area
of Granada province, serving a reference population of
around 440,000 inhabitants. Within this geographic area, we
compared data on 1,045 urine samples from the pediatric
population (under 2 years of age)with the previously reported
data on 31,758 samples, mainly from individuals over 14 years
of age.
In both cases, E. coli was the most frequently bacterium
isolated in urine samples of patients withUTI (60.3% in pedi-
atric population versus 55.2% in adult population), followed
by E. faecalis (22.4% versus 18.0%). The isolation frequency
of the remaining bacteria was also highly similar between
the studies. These data are consistent with previous findings
that E. coli is the most frequently isolated uropathogen at
all ages in our region and in other countries [17–21]. The
frequency of Enterococcus spp. in our setting was higher than
that of enterobacteria other than E. coli. Therapeutic recom-
mendations must take into account the reduced activity of
cephalosporins, aminoglycosides, and cotrimoxazole against
Enterococcus spp.
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Figure 1: Activity (in %) of the different antibiotics against all bacteria isolated in urine samples during 2011–2014.
In general, the bacteria isolated in young children were
more susceptible than those isolated in adults. A high
rate of resistance (20–30% of isolates in most years) was
found to antibiotics such as amoxicillin-clavulanic acid and
cotrimoxazole in E. coli and to nitrofurantoin in P. mirabilis
(main bacteria in the group of other Enterobacteriaceae).
The low frequency of ESBL-producing enterobacteria (1.1%)
and the elevated susceptibility of enterococci to the studied
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antibiotics would contribute to the higher bacterial sus-
ceptibility rates in the children. As observed by various
authors, increased resistance rates are associated with greater
exposure to antibiotics [4, 22, 23], and the lesser exposure
of infants in comparison to adults may also explain the
increased susceptibility of UTI isolates in the pediatric
population.
In agreement with our results, various Spanish studies
of pediatric populations have reported a high resistance
of E. coli to cotrimoxazole and variable rates of resis-
tance to amoxicillin-clavulanic acid (these antibiotics would
therefore not be suitable for empiric UTI treatment) but
an elevated susceptibility to second- and third-generation
cephalosporins, fosfomycin, nitrofurantoin, and aminoglyco-
sides [9, 24].Klebsiella spp. showed a high but widely variable
susceptibility to all study antibiotics, as previously reported in
our country [9, 24, 25]. However, antibiotic resistance rates
were higher for other enterobacteria (including the highly
frequent P. mirabilis) than for E. coli, as reported by some
uroculture studies in general and pediatric populations [9, 10,
24]. P. aeruginosa has classically demonstrated high suscep-
tibility to piperacillin-tazobactam, ceftazidime, carbapenems
(mainly imipenem), and aminoglycosides, as in the present
study [18, 25, 26]. Finally, although cephalosporins and
aminoglycosides are slightly superior against enterobacteria
in comparison to amoxicillin-clavulanic acid, Enterococcus
spp. is intrinsically resistant to these antibiotics. Hence,
amoxicillin-clavulanic acid, fosfomycin, or nitrofurantoin
can be used against these bacteria, whichwere highly frequent
in our study, although this is not necessarily the case in other
geographic areas of our country [25].
Based on different international recommendations, the
Spanish Association of Pediatrics has established precise
guidelines for the initial empiric treatment of UTIs accord-
ing to the age of the child. The recommendation in the
first three months of life, a period of maximum risk of
renal involvement and progression to sepsis, is parenteral
treatment with two antibiotics, optimally ampicillin with
an aminoglycoside (usually gentamicin) or cefotaxime at
doses recommended for neonatal sepsis. After resolution of
the clinical manifestations, these can be replaced with oral
antibiotic(s) (amoxicillin, with or without clavulanic acid,
cotrimoxazole, cefadroxil, or cefixime) for 10–14 days, after
examining the pattern of susceptibility of the causative agent
to antimicrobials and ruling out any urinary tract obstruc-
tion. For children over 3 months of age with moderate or
severe febrile UTI and moderate or severe clinical status, ini-
tial parenteral treatment with gentamicin or a cephalosporin
(cefotaxime, ceftriaxone, or cefuroxime) is recommended;
if the symptoms improve, the treatment can be continued
for 10–14 days in accordance with the uroculture results and
evaluation of the susceptibility of the agent. For children
over 3 months of age with febrile UTI but no impairment of
their general health status, oral treatment is recommended for
7–10 days; although various agents are valid options, clinical
guidelines in our setting recommend cefixime as the first
choice and cefuroxime as the second [27].
The activity of any antibiotic used for empiric UTI
treatment can be estimated a priori according to the incidence
of different pathogens and the accumulated resistance [10].
Some authors consider that an antibiotic with a rate of accu-
mulated bacterial resistance above 15% of isolates should not
be used in empiric therapy [9]. In this regard, the antibiotics
with highest activity (Figure 1) were piperacillin-tazobactam,
imipenem, fosfomycin, and nitrofurantoin, which are not
usually selected for empiric UTI treatment in young children.
In contrast, the antibiotics that were least active (resistance
rates >15% of isolates), that is, amoxicillin-clavulanic acid,
second- and third-generation cephalosporins, gentamicin,
and cotrimoxazole, are considered first-line antibiotics in the
clinical guidelines. As noted above, our findings are explained
by the high resistance of enterobacteria, especially E. coli,
to amoxicillin-clavulanic acid and cotrimoxazole, and by the
elevated frequency of E. faecalis isolates.
Some researchers found that children with acute pyelo-
nephritis were effectively treatedwith parenteral or oral doses
of amoxicillin-clavulanic acid in an area with a low resistance
rate [28]. However, in settings with higher resistance to
amoxicillin-clavulanic acid, such as ours, it is appropriate
to choose alternative antibiotics in accordance with local
susceptibility patterns. In most countries, resistance to cot-
rimoxazole and aminoglycosides, especially in Enterococcus
spp. but also in Enterobacteriaceae, is now so high that
they are no longer suitable for empiric UTI treatment in
young children [4, 11, 23]. In their place, cephalosporins
have become the empiric drug of choice, but uropathogen
resistance to cephalosporins is also increasing [4].
Among alternative options, nitrofurantoin is a bacterio-
static agent for Gram-positive bacteria but a bactericide for
Gram-negative bacteria and has been orally administered
to treat UTI in children aged over 2-3 years; moreover, the
susceptibility of E. coli to this drug remains high [4]. Some
studies have shown that the renal excretion of nitrofurantoin
is adequate, but it is not recommended in complicated UTI
because it is a bacteriostatic antibiotic in some cases [5].
However, its oral administration may be an option for the
empiric oral treatment of mild nonfebrile and/or localized
UTIs (cystitis and urethritis) in children over the age of 2
years. In these cases, another possibility is oral treatment with
fosfomycin, an active bactericide antibiotic against numerous
Gram-positive and Gram-negative bacteria species; high and
prolonged concentrations have been observed in urine, and it
has demonstrated effectiveness and good tolerance in young
children [29]. It could therefore also be considered in the
empiric oral treatment of mild nonfebrile and localized UTIs.
In children, it is exceptional to resort to antibiotics such
as carbapenems to cover possible multiresistant microor-
ganisms (e.g., ESBL-producing bacteria) given their low
frequency, as also observed in the present study [6]. In
general, these antibiotics are not recommended as first-line
treatments in children because of the risk of a rapid increase
in carbapenemase-producing bacteria [30]. Nevertheless,
their administration could be considered in severe cases of
febrile UTI in children.
Finally, the main study limitation was the inability to
stratify the population under investigation, because the
laboratory computer system from which identification and
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susceptibility data were drawn only gathers the informa-
tion required to correctly manage the process from request
reception to report delivery. Thus, the database does not
contain complete information on the sex of patients or on the
symptoms (fever,malodorous urine, irritability, poor feeding,
vomiting, abdominal distension, etc.) or type (complicated or
uncomplicated) of their ITU, among other data.This prevents
conclusions being drawn on the relationship between the
microorganisms or their resistance/susceptibility rates and
the characteristics of the study population.
5. Conclusion
In conclusion, E. coli was the most frequently isolated
bacterium in both community- and hospital-acquired UTIs
in our setting, while other bacteria such as E. faecalis
also represented a large proportion of the etiologic agents
detected. Amoxicillin-clavulanic acid, cephalosporins, gen-
tamicin, and cotrimoxazole may be inadequate for the
empiric treatment of community or hospital-acquired UTI
in children under the age of 2 years, because of the limited
activity of these antibiotics against uropathogens in our geo-
graphic area. Fosfomycin is an alternative in pediatric patients
with uncomplicated UTI, while piperacillin-tazobactam and
imipenem are options in more severe UTIs (e.g., neonates,
presence of anatomic abnormalities, immunodeficiency, or
urinary sepsis). Regular follow-ups are essential in each geo-
graphic area to establish local rates of uropathogen resistance
to available antibiotics, modifying the protocol for empiric
UTI treatment accordingly when changes are detected in the
susceptibility profiles of the bacteria.
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de los uropatógenos en la infancia (1995–2001),” Bolet́ın de la
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